home · filing · 0001104659-24-051944
8-K filed April 25, 2024, 7:59 PM ET
ticker IMNM
CIK 0001472012
leadership
confidence high
sentiment neutral
materiality 0.30
Immunome appoints Dr. Sandra Swain as Class III director, joins Audit Committee
Immunome Inc.
Appointment effective April 25, 2024; term expires at 2026 annual meeting.
Annual cash retainer: $40,000 for Board, $7,500 for Audit Committee membership.
Initial option grant of $270,000 Black-Scholes value, vesting quarterly over three years.
Isaac Barchas stepped down from Audit Committee; new members: Schafer (Chair), Swain, Bienaimé.
Dr. Swain also receives automatic annual option grants of $135,000 vesting over 12 months.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Appointed
Sandra Swain
Class III Director
Effective 2024-04-25
Filed April 25, 2024, 7:59 PM ET
appointed Sandra Swain, M.D. as a Class III director of the Company, with a term of office expiring at the 2026 annual meeting of stockholders.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Sandra Swain was appointed as Class III Director at Immunome Inc..
Action appointed
Role Class III Director
Exact text from the filing
appointed Sandra Swain, M.D. as a Class III director of the Company, with a term of office expiring at the 2026 annual meeting of stockholders.
View on SEC.gov
Source: SEC EDGAR
accession 0001104659-24-051944
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.